Anti-cancer effects of bortezomib against chemoresistant neuroblastoma cell lines in vitro and in vivo

  • Authors:
    • Martin Michaelis
    • Iduna Fichtner
    • Diana Behrens
    • Wolfram Haider
    • Florian Rothweiler
    • Andreas Mack
    • Jaroslav Cinatl
    • Hans Wilhelm Doerr
    • Jindrich Cinatl
  • View Affiliations

  • Published online on: February 1, 2006     https://doi.org/10.3892/ijo.28.2.439
  • Pages: 439-446
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The proteasome inhibitor bortezomib (Velcade®) was recently approved for the treatment of therapy-refractive multiple myeloma and is under investigation for numerous other types of cancer. A phase I clinical trial in paediatric patients resulted in tolerable toxicity. Since the emergence of chemoresistance represents one of the major drawbacks in cancer therapy, we investigated the influence of bortezomib on multi-drug resistant human neuroblastoma cell lines characterised by P-glycoprotein expression and p53 mutation. Nanomolar concentrations of bortezomib inhibited the cell cycle and induced apoptosis in chemosensitive as well as in chemoresistant cell lines. in vivo growth of chemosensitive and chemoresistant neuroblastoma cell lines was inhibited to a similar extent. In addition, bortezomib inhibited vessel formation in neuroblastoma xenografts. These findings and the favourable toxicity profile of bortezomib in children make it reasonable to further pursue additional development of the drug for the treatment of neuroblastoma and other paediatric solid tumours.

Related Articles

Journal Cover

February 2006
Volume 28 Issue 2

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Michaelis M, Fichtner I, Behrens D, Haider W, Rothweiler F, Mack A, Cinatl J, Doerr HW and Cinatl J: Anti-cancer effects of bortezomib against chemoresistant neuroblastoma cell lines in vitro and in vivo. Int J Oncol 28: 439-446, 2006.
APA
Michaelis, M., Fichtner, I., Behrens, D., Haider, W., Rothweiler, F., Mack, A. ... Cinatl, J. (2006). Anti-cancer effects of bortezomib against chemoresistant neuroblastoma cell lines in vitro and in vivo. International Journal of Oncology, 28, 439-446. https://doi.org/10.3892/ijo.28.2.439
MLA
Michaelis, M., Fichtner, I., Behrens, D., Haider, W., Rothweiler, F., Mack, A., Cinatl, J., Doerr, H. W., Cinatl, J."Anti-cancer effects of bortezomib against chemoresistant neuroblastoma cell lines in vitro and in vivo". International Journal of Oncology 28.2 (2006): 439-446.
Chicago
Michaelis, M., Fichtner, I., Behrens, D., Haider, W., Rothweiler, F., Mack, A., Cinatl, J., Doerr, H. W., Cinatl, J."Anti-cancer effects of bortezomib against chemoresistant neuroblastoma cell lines in vitro and in vivo". International Journal of Oncology 28, no. 2 (2006): 439-446. https://doi.org/10.3892/ijo.28.2.439